1415 W. Diehl Road
About physIQPhysIQ is a company dedicated to enabling proactive care delivery models through its Personalized Physiology Analytics (PPA) and highly scalable cloud-based platform. The FDA 510k-cleared data analytics platform is designed to process multiple vital signs from wearable sensors to create a personalized dynamic baseline for each individual. By mapping vital sign relationships this way, physIQ’s analytics detect subtle deviations that may be a precursor to disease exacerbation or change in health and warrant clinical attention. With applications in both healthcare delivery and clinical trial support, physIQ is transforming continuous physiological data into insight for providers, health systems, payers, and pharmaceutical and medical device companies.
Founder and CEO: Gary Conkright
Founder and CTO: Matt Pipke
CMO: Stephen Ondra
CSO: Stephan Wegerich
Please click here for physIQ job opportunities.
16 articles with physIQ
NorthShore University HealthSystem has joined physIQ’s NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker.
Intermountain Healthcare, UTHealth in Houston and Rush University Join PhysIQ’s Study to Develop COVID-19 Digital Biomarker
Digital health leader, physIQ Inc. , recently announced that Intermountain Healthcare Utah , The University of Texas Health Science Center at Houston (UTHealth) and Rush University Medical Center have joined the NIH-funded DeCODe study to develop an AI-based COVID-19 digital biomarker. These institutions will serve as recruiting centers and key partners in the Phase II validation stage of this study.
This DOD-funded initiative will assess the role of continuous biosensor data and artificial intelligence in addressing the COVID-19 pandemic.
physIQ, a leader in real-world biosensor data collection and digital biomarkers, announced a new multi-year collaboration to license physIQ’s accelerateIQTM to Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
physIQ, Inc. and the US Department of Veteran’s Affairs have advanced their collaboration to address heart failure care to an interventional trial phase.
PhysIQ and Purdue University launch study to develop algorithms for detecting earliest signs of COVID-19 from biometric smartwatch data
Certain changes in a person’s heart and breathing rates could precede symptoms of COVID-19, an increasing number of studies suggests. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200930005184/en/ Purdue University researchers are helping to develop physIQ software that could indicate that a person should get tested for COVID-19 by detecting s
NorthShore University HealthSystem, Carnegie Mellon University and PhysIQ Launch Comprehensive Study of New Technology to Monitor At-Risk Cardiac and Surgical Patients
NorthShore University HealthSystem, Carnegie Mellon University, and physIQ are collaborating on a multi-phase pilot project using the pinpointIQ™ solution to manage patients with heart failure and patients undergoing ileostomy.
physIQ, Department of Defense, and The Henry M. Jackson Foundation for The Advancement of Military Medicine Partner to Deploy Continuous Remote Monitoring Platform to Study COVID-19
This DOD-funded initiative will assess the role of home-based continuous biosensor data and AI analytics in addressing the global COVID-19 crisis.
PhysIQ uses over one million hours of training set data to implement new machine learning analytics aimed at detecting early signs of COVID-19.
PhysIQ’s Proprietary Personalized Analytics to be Used for COVID-19 Care with Newly Broadened FDA Labeling
PhysIQ announces FDA-sanctioned labeling to address the COVID-19 public health emergency with its proprietary Multivariate Change Index (MCI) Deployed within the pinpointIQ ® continuous remote monitoring solution, physIQ’s MCI will be used to proactively monitor homebound patients with or vulnerable to COVID-19 The sophisticated, machine learning-based algorithm uses multiple continuous vital signs from wearable sensors to detect subtle chan
PhysIQ and U.S. Veteran’s Affairs Publish Breakthrough Study Predicting Heart Failure Hospitalization up to 10 days in Advance using AI
PhysIQ and the U.S. VA publish results of a clinical trial that demonstrates how artificial intelligence (AI) applied to continuous wearable sensor data may predict hospitalizations.
PhysIQ Inc. Receives FDA Clearance of Continuous Ambulatory Respiration Rate Algorithm Enabling Artificial Intelligence-based Analytics for Biopharma Companies and Payers
FDA 510(k) cleared Respiration Rate analytic adds to physIQ’s growing portfolio of FDA 510(k) algorithms
- Omron HeartGuide®, the first wearable blood pressure device, will integrate with physIQ’s pinpointIQ® analytics platform to indicate a potential health risk - This combined solution is being deployed to help manage recently-discharged, at-risk patients - The goal is to provide clinicians with physiological insight to proactively address potential clinical deterioration
FDA 510(k) cleared Atrial Fibrillation (AFib) detection analytic adds to physIQ’s portfolio of FDA 510(k) algorithms
Netherlands-based Haga Teaching Hospital partners with physIQ and VitalConnect to continuously monitor cancer patients during treatment
Cancer patients are equipped with wearable biosensors for monitoring before, during and after cancer treatment